01651nam 2200445Ia 450 99638587700331620200824132945.0(CKB)4940000000075995(EEBO)2240967983(OCoLC)ocm12258632e(OCoLC)12258632(EXLCZ)99494000000007599519850712d1662 uy |engurbn||||a|bb|A defence of the doctrine touching the spring and weight of the air[electronic resource] /propos'd by Mr. R. Boyle in his new physico-mechanical experiments, against the objections of Franciscus Linus ; wherewith the objector's funicular hypothesis is also examin'd, by the author of those experimentsLondon Printed by F.G. for Thomas Robinson ...1662[12], 122 p., [1] leaf of plates illThis work contains the first formulation of Boyle's law.Edited by Robert Sharrock.Errata: p. 122.Reproduction of original in British Library.eebo-0018AirEarly works to 1800Air-pumpEarly works to 1800PhysicsExperimentsEarly works to 1800AirAir-pumpPhysicsExperimentsBoyle Robert1627-1691.67901Sharrock Robert1630-1684.1005512EAAEAAm/cEAAWaOLNBOOK996385877003316A defence of the doctrine touching the spring and weight of the air2329883UNISA01003nam0 22002651i 450 UON0039377420231205104624.65120110610d1923 |0itac50 barumRO|||| 1||||George CosbucStudiu criticConstanta MarinescuBucurestiEditura Literara a Casei Scoalelor1923336 p.20 cm.COSBUC GEORGEUONC074181FIROBucureştiUONL000071859Letteratura romena e letterature ladine21MARINESCUConstantaUONV202574705674Casa ScoalelorUONV275674650ITSOL20240220RICASIBA - SISTEMA BIBLIOTECARIO DI ATENEOUONSIUON00393774SIBA - SISTEMA BIBLIOTECARIO DI ATENEOSI FONDO ONCIULESCU B 0342 SI MR 73995 7 0342 DeterioratoGeorge Cosbuc1350481UNIOR05123nam 2201213z- 450 991055748970332120220111(CKB)5400000000042934(oapen)https://directory.doabooks.org/handle/20.500.12854/77051(oapen)doab77051(EXLCZ)99540000000004293420202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNon-small Cell Lung Cancer: Current Therapies and New Targeted TreatmentsBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (258 p.)3-0365-0130-4 3-0365-0131-2 Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.Non-small Cell Lung CancerMedicinebicsscadjuvant chemotherapybiomarkerchemotherapydaily practiceDNA polymerase betadocetaxelEGFR-TKIendocrine disordersepidermal growth factor receptorExpanded Access ProgramFDG-PETgenomic diagnosisglucose transporter 1HIP1Rimmune checkpoint inhibitorimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapyinterstitial lung diseaseKRASlung cancerlung neoplasmsmeta-analysismetastasismethylationmultiple cancersmutationnetwork meta-analysisnivolumabnon-small cell lung cancernon-small-cell lung cancernonsmall cell lung cancerNSCLCnucleotide-diphosphate kinaseoligometastasisosimertinibPD-1PD-1 blockadePD-1 inhibitorsPD-L1PD-L1 expressionPD-L1 inhibitorsphase I/II trialplatinum-based first-linepredictive biomarkerpreviously treated patientsprognosisprognostic factorprognostic factorspulmonary fibrosispulmonary pleomorphic carcinomaRAD51B methylationradiology and other imagingreal-world datarechallengerecurrenceresponsivenessretrospective analysisRUNX1S-1salvage surgerysequencingstage IIIA-N2surgerysurvivalT790Mtargeted therapyTP53 mutationstumor-bearing patientstyrosine kinase inhibitorsunresectableβ-cateninMedicineUchino Junjiedt1302981Uchino JunjiothBOOK9910557489703321Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments3026799UNINA